Ciltacabtagene Autoleucel
This page contains brief information about ciltacabtagene autoleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Ciltacabtagene autoleucel is approved to treat:
- Multiple myeloma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults who have received at least four treatments that included an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating agent.
Ciltacabtagene autoleucel is only available as part of a special program called Carvykti REMS (Risk Evaluation and Mitigation Strategies).
More About Ciltacabtagene Autoleucel
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma
FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma
NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials
CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers
Clinical Trials Accepting Patients
Find Clinical Trials for Ciltacabtagene Autoleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.